Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association for Cancer Research (AACR) Meeting

NATICK, Mass., March 26, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces fifteen (15) poster presentations covering its Selective Inhibitors of Nuclear Export (SINE), oral small molecule XPO1/CRM1 antagonists, at the AACR meeting on April 6 – 13, 2013, in Washington DC. Karyopharm's lead oral XPO1 inhibitor KPT-330 is currently in Phase 1 testing in adult patients with advanced hematologic and solid tumors (NCT01607892, NCT01607905). Karyopharm's related oral XPO1 inhibitor KPT-335 is currently in a potentially pivotal study in dogs with spontaneous non-Hodgkin's lymphomas.

Back to news